KSPM
Search
- Page Path
- HOME > Search
English Abstracts
- Guidelines for Economic Evaluation of Pharmaceuticals in Korea.
- Eun Young Bae
- J Prev Med Public Health. 2008;41(2):80-83.
- DOI: https://doi.org/10.3961/jpmph.2008.41.2.80
- 5,388 View
- 89 Download
- 13 Crossref
-
Abstract
PDF - An economic evaluation is required in order to apply to the Health Insurance Review and Assessment Service (HIRA) for a listing in the national drug formulary. To assist companies in preparing the necessary documents, HIRA published guidelines for the economic evaluation of pharmaceuticals in 2006. The guidelines are composed of two parts: guidance an explanatory notes. Each guideline reflects the best practice which meets both the theoretical consensus within the academic community and local situations, like data availability. To enhance the transparency of evaluation, guidelines emphasize the reproducibility of data and analysis result. That is, all evaluation processes are required to be described in enough detail to be replicated by reviewers. With growing experience and theoretical development in this area, HIRA guidelines will be revised periodically.
-
Summary
Citations
Citations to this article as recorded by
- Cost-Effectiveness and Value of Information of Cabozantinib Treatment for Patients with Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea
Siin Kim, Sola Han, Hyungtae Kim, Hae Sun Suh
Applied Health Economics and Health Policy.2021; 19(4): 545. CrossRef - Cost-Effectiveness Analysis of Hypertension Screening in the Korea National Health Screening Program
Hae-Young Lee, Seung Won Lee, Hyeon Chang Kim, Sang Hyun Ihm, Sung Ha Park, Tae Hyun Kim
Korean Circulation Journal.2021; 51(7): 610. CrossRef - Analysis of Anesthesia Methods in Percutaneous Kyphoplasty for Treatment of Vertebral Compression Fractures
Jie Liu, Lin Wang, Mei Chai, Junjie Kang, Jie Wang, Yanjun Zhang
Journal of Healthcare Engineering.2020; 2020: 1. CrossRef - Efficacy, safety, and economic assessment of hominis placental pharmacopuncture for chronic temporomandibular disorder: a protocol for a multicentre randomised controlled trial
Jongho Kim, Kyoung Sun Park, Yoon Jae Lee, Koh-Woon Kim, Jae-Heung Cho, In-Hyuk Ha
Trials.2020;[Epub] CrossRef - Cost-utility analysis of extensile lateral approach versus sinus tarsi approach in Sanders type II/III calcaneus fractures
Zihua Li, Xinbo Wu, Haichao Zhou, Shaochen Xu, Fajiao Xiao, Hui Huang, Yunfeng Yang
Journal of Orthopaedic Surgery and Research.2020;[Epub] CrossRef - A Cost-utility Analysis of Percutaneous Endoscopic Lumbar Discectomy for L5-S1 Lumbar Disc Herniation
Dongdong Wang, Wangcheng Xie, Wenxin Cao, Shisheng He, Guoxin Fan, Hailong Zhang
Spine.2019; 44(8): 563. CrossRef - Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea
Sun-Kyeong Park, Sung-Hyun Hong, HyoJin Kim, Sungju Kim, Eui-Kyung Lee
Clinical Therapeutics.2019; 41(6): 1066. CrossRef - Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea
Donghoon Lee, Hyun-Young Shin, Sang Min Park
Cost Effectiveness and Resource Allocation.2018;[Epub] CrossRef - Single balloon versus double balloon bipedicular kyphoplasty: a systematic review and meta-analysis
Zehao Jing, Jianli Dong, Zhengwei Li, Feng Nan
European Spine Journal.2018; 27(10): 2550. CrossRef - Estimating utility weights and quality-adjusted life year loss for colorectal cancer-related health states in Korea
Jin Yong Lee, Minsu Ock, Min-Woo Jo, Woo-Seung Son, Hyeon-Jeong Lee, Seon-Ha Kim, Hyun Joo Kim, Jong Lyul Lee
Scientific Reports.2017;[Epub] CrossRef - Cost-Utility Analysis of Pedicle Screw Removal After Successful Posterior Instrumented Fusion in Thoracolumbar Burst Fractures
Han-Dong Lee, Chang-Hoon Jeon, Nam-Su Chung, Young-Wook Seo
Spine.2017; 42(15): E926. CrossRef - Estimation of utility weights for human papilloma virus-related health states according to disease severity
Minsu Ock, Jeong-Yeol Park, Woo-Seung Son, Hyeon-Jeong Lee, Seon-Ha Kim, Min-Woo Jo
Health and Quality of Life Outcomes.2016;[Epub] CrossRef - Assessment of Pharmacoeconomic Evaluations Submitted for Reimbursement in Korea
Eun-Young Yim, Sang Hee Lim, Mi-Jeong Oh, Hye Kyung Park, Ji-Ryoun Gong, Sung Eun Park, So Young Yi
Value in Health.2012; 15(1): S104. CrossRef
- Use of Economic Evaluation in the Listing and Pricing of Pharmaceuticals.
- Tae Jin Lee
- J Prev Med Public Health. 2008;41(2):69-73.
- DOI: https://doi.org/10.3961/jpmph.2008.41.2.69
- 4,454 View
- 56 Download
- 5 Crossref
-
Abstract
PDF
- To curb a rapid increase in expenditures for pharmaceuticals, the Korean government introduced a positive list system and a negotiation process for drug prices at the end of 2006. Economic evaluation of pharmaceuticals has begun to have a pivotal role in the listing and pricing of drugs for the Korean National Health Insurance. There are some points to discuss regarding the use of economic evaluation in the listing and pricing in the context of the Korean system. First, the listing and pricing processes have been fragmented, evoking complaints from pharmaceutical companies and delaying the access of new drugs to patients. Second, there is a concern that the positive list system may limit the range and availability of drugs for patients to choose for treatment. Third, the time schedule for de-listing of existing drugs may not be realistic. Fourth, it is not always easy to provide reliable evidence of cost-effectiveness due to a lack of materials. Fifth, there is no consensus on the range of the ICER (incremental cost-effectiveness ratio) acceptable to the Korean society. In conclusion, in the near future, it will be necessary to evaluate the achievements that the economic evaluation has provided to the Korean society.
-
Summary
Citations
Citations to this article as recorded by- Cost-effectiveness of rhythm control strategy: Ablation versus antiarrhythmic drugs for treating atrial fibrillation in Korea based on real-world data
Woojin Kim, Min Kim, Yun Tae Kim, Woongbi Park, Jin-bae Kim, Changsoo Kim, Boyoung Joung
Frontiers in Cardiovascular Medicine.2023;[Epub] CrossRef - Policy Suggestions to Improve Patient Access to New Drugs in Korea
Yoona Choi, Howard Lee
Korean Journal of Clinical Pharmacy.2021; 31(1): 1. CrossRef - Consistency of new drug pricing in Korea: Bridging variations among personnel in price negotiations
Hye-Young Kwon, Jinhyun Kim
Health Policy.2020; 124(9): 965. CrossRef - How Much Amount of Socioeconomic Loss Is Caused by Digestive Diseases?
Kyung Sik Park
The Korean Journal of Gastroenterology.2011; 58(6): 297. CrossRef - Health Care Costs of Digestive Diseases in Korea
Hye-kyung Jung, BoHyoung Jang, Youn Hee Kim, JooYeon Park, Sun Young Park, Mi-Hee Nam, Myung-Gyu Choi
The Korean Journal of Gastroenterology.2011; 58(6): 323. CrossRef
First
Prev
